Maravai LifeSciences and GTCR Complete Acquisition of Solulink Commercial Assets

SAN DIEGO, CA (December 27, 2016) Maravai LifeSciences (“Maravai”), a leader in providing specialty reagents to life sciences researchers, biotherapeutics manufacturers and OEM partners worldwide, today announced it has completed the acquisition of the commercial assets of Solulink Incorporated (“Solulink”).  The Solulink assets will be part of the product portfolio offered by Maravai’s TriLink BioTechnologies (“TriLink”) subsidiary.

Read More
walter Lentfert
GTCR and Maravai Complete Acquisitions of TriLink Biotechnologies and Cygnus Technologies

Expands Maravai’s Strategy in Specialty Research Reagents and Adds Bioprocessing Leader

GTCR, a leading private equity firm, today announced that it has completed the acquisitions of TriLink Biotechnologies, LLC ("TriLink") and Cygnus Technologies, Inc. ("Cygnus"), adding to its Maravai LifeSciences ("Maravai") platform.  The acquisitions further Maravai's strategy of building a leading company focused on specialized research reagents and expand the portfolio with key bioprocessing capabilities.  

Read More
walter Lentfert
GTCR and Maravai Complete Strategic Equity Investment in Vector Laboratories

GTCR, a leading private equity firm, today announced that it has completed a strategic equity investment in Vector Laboratories, Inc. ("Vector" or the "Company"), through GTCR’s previously established Maravai LifeSciences ("Maravai") management partnership with CEO Carl Hull.  Vector is a leading provider of life science products, including labeling and detection reagents, that help medical and scientific researchers visualize cells in experiments which are central to the understanding of cancer and other diseases. 

Read More
walter Lentfertmaravai
GTCR Announces Partnership with Carl Hull and Eric Tardif to Form Maravai Life Sciences

Chicago, IL, GTCR, a leading private equity firm, today announced that it has entered into a partnership with Carl Hull and Eric Tardif to form Maravai LifeSciences, Inc. (“Maravai”). The new company, headquartered in San Diego, California, will focus on acquiring companies and products in the diagnostics and life sciences industry as part of a strategy to build a market leading healthcare business. GTCR will invest up to $300 million of equity capital to support management’s strategy.

Read More
walter Lentfert